HNF-1β in Ovarian Carcinomas with Serous and Clear Cell Changes
Robert A Soslow, Guangming Han, C Blake Gilks, Deborah DeLair. Memorial Sloan-Kettering Cancer Center, New York, NY; Vancouver General Hospital, Vancouver, Canada; University of Calgary, Calgary, Canada
Background: Many ovarian tumors show clear cell change including high grade serous carcinomas (SC). Accurate diagnosis is important, however, as ovarian clear cell carcinoma (CCC) is well-known to be less responsive than SC to traditional types of ovarian carcinoma chemotherapies. In a previous study, 32 ovarian carcinomas originally diagnosed as pure CCC (n=11), mixed serous and clear cell (MSC) (n=10), or pure SC (n=11), were evaluated to determine cell type. Parameters evaluated included clinical, morphologic, and immunohistochemical features. In this study, MSC showed mitotic rates, stages of presentation, and immunoreactivities of the markers WT1, ER, and p53 similar to that of SC. It was thus concluded that MSC represent SC with clear cell change. HNF-1β, an immunohistochemical marker which has been shown to be rather specific for CCC was not evaluated in this study. We thus sought to analyze this marker in this group of tumors.
Design: One block of each of the SC and CCC was stained with the immunohistochemical marker HNF-1β. In the cases of MSC, 2 blocks were evaluated when the serous and clear cell components were not present on the same slide.
Results: The results of the immunohistochemical analysis are shown in the table below.
|Tumor type||# HNF-1ß + cases|
|Clear cell component of MSC||0/10|
|Serous component of MSC||0/10|